In a phase 1 study of 10 adults with advanced retinitis pigmentosa, researchers found that optogenetic gene therapy combined with light-stimulating goggles was generally well tolerated, although one participant experienced a severe but transient ocular adverse event. Seven participants showed improved light sensitivity, while four of eight who completed behavioral testing demonstrated modest gains in visual function, providing preliminary evidence of partial vision restoration that requires confirmation in larger controlled trials.